Autoimmune Disease Drugs Market Research Report by Indication, Drug Class, Distribution, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

The Global Autoimmune Disease Drugs Market size was estimated at USD 94.40 billion in 2021 and expected to reach USD 101.24 billion in 2022, and is projected to grow at a CAGR 7.42% to reach USD 145.07 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Autoimmune Disease Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Indication, the market was studied across Diabetes Mellitus Type 1, Multiple Sclerosis, Rare Diseases, and Rheumatic Diseases.

Based on Drug Class, the market was studied across Anti-inflammatory, Antihyperglycemic, Immunosuppressants, Interferons, and NSAIDs.

Based on Distribution, the market was studied across Hospital Pharmacies, Online Stores, and Retail Pharmacies.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Autoimmune Disease Drugs market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Autoimmune Disease Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Autoimmune Disease Drugs Market, including Abbott Laboratories, AbbVie Inc., Active Biotech, Amgen Inc., AstraZeneca PLC, AutoImmune Inc., Bio-rad Laboratories, Biogen Inc., Biomérieux SA, Bristol-Myers Squibb Company, Cadila Healthcare Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Genentech, Inc, GlaxoSmithKline PLC, Idera Pharmaceuticals, Inc., Johnson & Johnson Services, Inc, Lupin Limited, Miltenyi Biotec, Myriad Genetics, Novartis AG, Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Trinity Biotech PLC, and UCB S.A..

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Autoimmune Disease Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Autoimmune Disease Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Autoimmune Disease Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Autoimmune Disease Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Autoimmune Disease Drugs Market?
6. What is the market share of the leading vendors in the Global Autoimmune Disease Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Autoimmune Disease Drugs Market?

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of autoimmune diseases rheumatoid arthritis and Graves and Hashimoto's thyroid disease
5.1.1.2. Awareness among public about autoimmune diseases and favourable government initiatives
5.1.1.3. Improved government assistance, funding, and reimbursement policies
5.1.2. Restraints
5.1.2.1. Slow turnaround time and recurrence post treatment
5.1.3. Opportunities
5.1.3.1. Advancements and availability of late-stage pipeline drugs
5.1.3.2. Strategic partnerships and investments between physicians and drug manufacturers
5.1.4. Challenges
5.1.4.1. Cost associated with the diagnosis process
5.2. Cumulative Impact of COVID-19

6. Autoimmune Disease Drugs Market, by Indication
6.1. Introduction
6.2. Diabetes Mellitus Type 1
6.3. Multiple Sclerosis
6.4. Rare Diseases
6.5. Rheumatic Diseases

7. Autoimmune Disease Drugs Market, by Drug Class
7.1. Introduction
7.2. Anti-inflammatory
7.3. Antihyperglycemic
7.4. Immunosuppressants
7.5. Interferons
7.6. NSAIDs

8. Autoimmune Disease Drugs Market, by Distribution
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Stores
8.4. Retail Pharmacies

9. Americas Autoimmune Disease Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Autoimmune Disease Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Autoimmune Disease Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Abbott Laboratories
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AbbVie Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Active Biotech
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Amgen Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. AstraZeneca PLC
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. AutoImmune Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Bio-rad Laboratories
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Biogen Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Biomérieux SA
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Bristol-Myers Squibb Company
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Cadila Healthcare Limited
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Eli Lilly and Company
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. F. Hoffmann-La Roche AG
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Genentech, Inc
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. GlaxoSmithKline PLC
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Idera Pharmaceuticals, Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Johnson & Johnson Services, Inc
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Lupin Limited
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Miltenyi Biotec
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Myriad Genetics
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Novartis AG
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Pfizer Inc.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Sanofi S.A.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. Thermo Fisher Scientific Inc.
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Trinity Biotech PLC
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
13.26. UCB S.A.
13.26.1. Business Overview
13.26.2. Key Executives
13.26.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing